Medical Developments International announce new partnership agreement with Labatec

MDI is excited to announce a new partnership agreement with Labatec. This partnership demonstrates our ongoing commitment to ensuring patient access to treatment.

MDI’s CEO, Brent MacGregor said, “Our transition to a partner-supported operating model in Switzerland aims to accelerate product accessibility. Labatec has extensive market access and deep customer relationships. We are excited to welcome Labatec as a new partner.”

A note from our new partner, Labatec:

“We are thrilled to partner with Medical Developments International to take over the commercialisation of a product in pain management in Switzerland. This collaboration underscores Labatec’s commitment to expanding access to innovative treatments that can make a meaningful impact on patient care. We are excited to work together to ensure that Swiss healthcare providers and patients continue to benefit from this important therapy.”
Marine Lazouret, Labatec Pharma SA, Switzerland

Enquiries

Medical Developments International: info@medicaldev.com